1. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial 
Solange Peters, MD, PhD, Rolf A. Stahel, MD, Urania Dafni, ScD, Santiago Ponce Aix, MD, Bartomeu Massutí, MD, Oliver Gautschi, MD, Linda Coate, MD, Ana López Martín, MD, PhD, Robbert van Heemst, MD, Thierry Berghmans, MD, PhD, Peter Meldgaard, MD, PhD, Manuel Cobo Dols, MD, Javier Garde Noguera, MD, Alessandra Curioni-Fontecedro, MD, Daniel Rauch, MD, Michael T. Mark, MD, Sinead Cuffe, MD, Bonne Biesma, MD, PhD, Arjen M.J. van Henten, MD, Óscar Juan Vidal, MD, PhD, Ramón Palmero Sanchez, MD, José Carlos Villa Guzmán, MD, Ricardo Collado Martin, MD, Sergio Peralta, MD, Amelia Insa, MD, Yvonne Summers, MD, István Láng, MD, PhD, ScD, Anne Horgan, MB, Fortunato Ciardiello, MD, PhD, Sander de Hosson, MD, Remge Pieterman, MD, PhD, Harry J.M. Groen, MD, PhD, Paul M. van den Berg, MD, Christoph C. Zielinski, MD, Yojena Chittazhathu Kurian Kuruvilla, MD, Adriana Gasca- Ruchti, MD, Marie Kassapian, PhD, Silvia Novello, MD, PhD, Valter Torri, MD, Zoi Tsourti, PhD, Vanesa Gregorc, MD, Egbert F. Smit, MD, PhD 
Journal of Thoracic Oncology 
Volume 12, Issue 4, Pages (April 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
CONSORT diagram of the EMPHASIS trial. pt, patient; ITT, intent-to-treat; PFS; progression-free survival; f-up, follow-up.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Kaplan-Meier survival curves for progression-free survival (PFS) and overall survival (OS) in the EMPHASIS-lung cohort (N = 80). (A) PFS by treatment arm and VeriStrat status. (B) OS by VeriStrat status. (C) OS by treatment arm and VeriStrat status. E-Good, VeriStrat good patients in the erlotinib arm; E-Poor, VeriStrat poor patients in the erlotinib arm; D-Good, VeriStrat good patients in the docetaxel arm; D-Poor, VeriStrat poor patients in the docetaxel arm.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 2
Kaplan-Meier survival curves for progression-free survival (PFS) and overall survival (OS) in the EMPHASIS-lung cohort (N = 80). (A) PFS by treatment arm and VeriStrat status. (B) OS by VeriStrat status. (C) OS by treatment arm and VeriStrat status. E-Good, VeriStrat good patients in the erlotinib arm; E-Poor, VeriStrat poor patients in the erlotinib arm; D-Good, VeriStrat good patients in the docetaxel arm; D-Poor, VeriStrat poor patients in the docetaxel arm.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

5. Figure 3
Forest plot of the effect of treatment and VeriStrat status (VS) on progression-free survival (PFS) and overall survival (OS) shown individually for each trial (EMPHASIS-lung and PROSE) and for the combined cohort. E, erlotinib; D, docetaxel; HR, hazard ratio; CI, confidence interval; PROSE-sq, squamous cell cohort from the PROSE trial; VSG, VeriStrat good; VSP, VeriStrat poor.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions